T HE role of angiotensin I (AI) converting enzyme or kininase II in the metabolism ofvasoactive peptides is generally recognized. It is probable that many patients suffering from hypertension or myocardial insufficiency will be treated in the future with an inhibitor of the enzyme. In spite of its importance, most of our knowledge of converting enzyme stems from experiments utilizing enzyme purified from animal organs.
T HE role of angiotensin I (AI) converting enzyme or kininase II in the metabolism ofvasoactive peptides is generally recognized. It is probable that many patients suffering from hypertension or myocardial insufficiency will be treated in the future with an inhibitor of the enzyme. In spite of its importance, most of our knowledge of converting enzyme stems from experiments utilizing enzyme purified from animal organs.
Recently, we completed a large-scale purification of human converting enzyme from lung and kidney.
1 ' 2 Thus, we decided to study the properties of the human enzyme, especially its inhibition by a new type of inhibitor in vitro. The inhibitor, ketoACE (5S-5-benzamido-4-oxo-6-phenylhexanoyl-L-proline), a ketomethylene derivative of the blocked tripeptide substrate, Bz-Phe-Gly-Pro, was developed by Almquist et al. 3 at SRI International. It differs from the substrate in that the labile second peptide bond between Phe and Gly (-C-NH-) has been replaced by a non-hydrolyzable ketomethylene linkage O (-C-CH,-). Our interest in alternative inhibitors of converting enzyme stems partly from the fact that clinical trials with captopril (SQ 14,225) have indicated some potentially serious side effects/ presumably related to the chemically active sulfhydryl group which is essential for the action of this drug. 8 For example, captopril can act as a reducing agent in vitro,' cleaving the S-S bridges in gamma globulin and in other proteins and peptides. The structure of ketoACE suggests that it may have no such side effects. We have investigated the effects of ketoACE on the hydrolysis of Hip-His-Leu and Hip-Phe-Arg, peptides representing the C-terminal dipeptides of angiotensin I and bradykinin. The results indicate that ketoACE and captopril differ in their mode of inhibition and provide some insight into the nature of the active site of the enzyme.
Materials and Methods
KetoACE was a gift from Ronald Almquist. HipHis-Leu, Hip-Phe-Arg, and Hip-Gly-Gly were purchased from Bachem. Randomly tritiated Hip-GlyGly (New England Nuclear Company) was purified to homogeneity by ion exchange on Cellex-D.
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imidazole was from Sigma. The inhibitor, /3-phenylpropionyl-L-phenylalanine, T was synthesized via the N-hydroxysuccinimide ester of /9-phenylpropionic acid (Aldrich). The product was recrystallized twice in ethanol: water, 2:1. All other chemicals were reagent grade.
The purification of human lung and kidney converting enzyme is described in detail elsewhere. 1 Briefly, the enzyme was solubilized from the membrane fraction by trypsin and purified by ion-exchange chromatography on DEAE-cellulose, gel filtration on Sephacryl S-300, hydroxyapatite chromatography, and hydrophobic chromatography on PhenylSepharose 4B. The enzyme, purified 5000-fold from human lung and 890-fold from kidney, with an overall yield of about 5%, was homogeneous in polyacrylamide gel aminoelectrophoresis. The lung and kidney enzymes had final specific activities of 37 and 30 U/mg when assayed with Hip-His-Leu under assay conditions described by Cheung and Cushman. 8 The studies described here were performed with the kidney preparation.
Kinetic measurements were made using a Cary 118 spectrophotometer.
1 -* The rates of hydrolysis were determined by measuring the increase in absorption at 254 nm using Ae M of 520 and 570 for Hip-His-Leu and Hip-Phe-Arg respectively. Depending on the concentration of substrate, semimicro quartz cuvets with path lengths of 0.1, 0.5, or 1.0 cm were used. Enzyme (0.03 to 0.2 U with Hip-His-Leu) was preincubated for 10 minutes at 37°C in the presence of the indicated concentrations of ketoACE in 0.1 M Hepes buffer, pH 8.0, containing 0.1 M NaCl. In control studies, HipGly-Gly 11 a was the substrate. Reaction rates were determined within 30 seconds after adding substrate. Each measurement was done in duplicate or triplicate. Double-reciprocal lines were determined by the method of least squares. At lower enzyme concentrations, converting enzyme activity was measured using randomly labeled 'H-Hip-Gly-Gly as the substrate by a modification of the procedures of Cushman and Cheung 8 and Ryan et al. 9 Chemical modification 10 of human kidney converting enzyme with N-acetylimidazole* in the presence and absence of inhibitors was carried out in 50 mM borate buffer at pH 7.5. Enzyme (approximately 1 U of activity for each experiment) was preincubated at room temperature with or without inhibitor for 30 minutes before the addition of N-acetylimidazole in the same buffer (final concentration = 5mM). Enzyme activity was regenerated by adding an equal volume of 0.1 M hydroxylamine (Aldrich) at pH 7.0. Reactions were stopped by passing aliquots of the reaction mixtures through small desalting columns (PD-10 disposable columns, Pharmacia) at the indicated times. Inhibitors were removed (about 90% recovery of activity) by extensive dialysis for 48 hours vs 20 mM potassium phosphate, pH 7.0 at 4°C. Under these conditions, the potentially reversible tyrosine modification 11 was stable as determined in a control experiment. Enzymatic activity of modified enzymes was assessed using Hip-Gly-Gly as substrate.
Results

I u Values
Initial observations by Almquist et al. s and by us indicated that ketoACE inhibited Hip-His-Leu hydrolysis by converting enzyme in a noncompetitive manner, i.e., it bound to a site other than the active site of the enzyme. This was difficult to understand for a substrate analog inhibitor and prompted our interest. We studied the inhibition further, using as substrates Hip-His-Leu and Hip-Phe-Arg, which represent the C-terminal dipeptides of angiotensin I and bradykinin. Unlike captopril, which inhibits the hydrolysis of both substrates with an I M of 2 X 10~* M, we found that ketoACE inhibited Hip-His-Leu more effectively than Hip-Phe-Arg ( fig. 1) . The I M values were 4 X 10"' and 2 X 10"' M. Because of the dependence of I M on enzyme concentration with inhibitors of high affinity, 11 the minimum I M value possible under standard spectrophotometric assay conditions is in the order of 10~8 M. Under the same conditions, the I M for ketoACE with Hip-Gly-Gly as substrate was 5 X 10 8 M. By using 'H-Hip-Gly-Gly and much lower enzyme concentrations (=*10~1 0 M), the I 80 for ketoACE was 6 X 10" M while that of captopril was 3 X 10-" M.
Kinetic Analyses
The results of kinetic experiments with ketoACE using Hip-His-Leu as substrate are shown in figure 2. Double reciprocal plots (figure 2, left graph) suggested noncompetitive inhibition, i.e., a change in V m , x while K m (=1.4 mM) remained unaltered. Plotting the data according to the technique of Dixon et al.
u ( fig. 2, right graph) showed that the inhibition was not simple noncompetitive. The 1/V vs I curves were convex downward and appeared to approach a limit at 
Chemical Modification
To elucidate the binding site of ketoACE, we studied its ability to block a chemical modification. Human converting enzyme, just as rabbit lung 7 or equine plasma 13 converting enzyme, probably contains an essential tyrosine residue. Treatment of the enzyme with 5 mM N-acetylimidazole in borate buffer at pH 7.5 reduced the activity to 5% of control in 30 minutes 100
FIGURE 3. Changes in the activity of human kidney converting enzyme modified with 5 mM N-acetylimidazole and after addition of 50 mM hydroxylamine at 30 minutes (o o). Effect of 5 mM N-acetylimidazole in the presence of 10 mM P-phenyl-propionyl-L-phenylalanine (A k) or I mM keloA CE ( • • ). Activity expressed as percent of control.
( fig. 3) . The activity was partially recovered (to about 75% of control) by treatment with 50 mM hydroxylamine, indicating reversible modification of a tyrosine residue in the active site. There was no loss of activity when the reaction was performed in the presence of 10 mM /3-phenyl-propionyl-L-phenylalanine, 7 a competitive inhibitor of converting enzyme, while in the presence of 1 mM ketoACE, the enzyme retained 80% of control activity. In other experiments, 0.01 mM ketoACE blocked 50% of the inactivation by Nacetylimidazole. These results demonstrate that ketoACE binds very near to the active site of human converting enzyme.
Discussion
The large-scale purification of membrane-bound human converting enzyme has allowed us to begin an investigation of its hydrolysis of natural and synthetic substrates and its inhibition by high affinity inhibitors, e.g., ketoACE. Human lung and kidney converting enzymes appear to be structurally very similar or identical although one originates from vascular endothelial cells in the lung and the other from proximal tubular cells in kidney.
1 -2 We noted differences in their carbohydrate composition: only human lung has forms with lower isoelectric points' 14 enriched in sialic acid. Kinetic parameters with synthetic substrates are similar for the two enzymes. Bradykinin is the best natural substrate as judged by its relatively high specificity constant (k c a t /K m = 500 min'VM" 1 ) as compared to AI. Met 5 and Leu'-enkephalins are also hydrolyzed by human converting enzyme; these substrates have high turnover numbers but their specificity constants are lowered by relatively high K m . In the present study, we have used the enzyme purified from human kidney, which has five times more activity per unit weight than that from the lung.
Our results suggest that the kinetics of inhibition by ketoACE are not simple. For the purpose of discussion, however, we will consider the simplest rapidequilibrium system that will give nonlinear Dixon plots of the type we have observed. The equilibria describing this system, called partial noncompetitive inhibition, are: K., k p E + S ^ E S -* E + P I JFK, I UK, p El + S = ESI -> E + P This mechanism differs from simple noncompetitive inhibition in that the ESI complex that forms is partially active 03 =f 0). This results in Dixon plots that are hyperbolic, curving downward. In this model, inhibitor and substrate both bind to the enzyme at the same time with no effect on the binding constant of the other. This results in a Lineweaver-Burk plot of the noncompetitive type (figure 2 left, K m is unchanged). I50 values, however, depend not only on K m and enzyme concentration, but also on /?. This may explain the difference in the I M values obtained with Hip-HisLeu and Hip-Phe-Arg: it suggests that these substrates bind in different ways to the active site and their catalytic constants are altered in different ways by ketoACE. The difference in the I M values of ketoACE with Hip-His-Leu and Hip-Phe-Arg is consistent with the known importance of the C-terminal two amino acids in the hydrolysis of substrates.
18 ' " Based on the kinetic and chemical modification experiments, we suggest that ketoACE inhibits human converting enzyme by binding to a hydrophobic site that partially overlaps with the active site. In the design of this inhibitor, Almquist et al.' noted the importance of a phenylalanine residue in the third position. Changing this residue to a smaller or polar residue greatly reduced the hydrolysis of substrate analogs or the affinity of inhibitor analogs. The importance of a hydrophobic residue in this position was also stressed by Bflnning et al., 16 who studied substrate specificity and kinetic characteristics of rabbit lung converting enzyme. Harris et al. 1 " have shown that derivatives of captopril with blocked sulfhydryl groups display apparent noncompetitive inhibition. It seems probable that these inhibitors bind to the hydrophobic site proposed for ketoACE.
The type of binding by natural substrates may determine their dependence on Cl~ for hydrolysis. Theoretically, if natural substrates bind in different manners to the active site, it should be possible to design inhibitors that would inhibit the cleavage of various peptides more selectively. Since ketoACE inhibits Al conversion competitively, 1 this indicates that longer polypeptide substrates may bind to an extended active site which includes the hydrophobic site proposed for ketoACE. The situation seems to be analogous to that described for carboxypeptidase B, which has an extended hydrophobic site. 17 Thus, a new class of compounds, which, like ketoACE, bind to a hydrophobic region in the active site of converting enzyme, could offer promise as effective inhibitors. Such inhibitors without the reactive -SH group essential for the action of captopril 11 may have fewer side effects.
